- Current report filing (8-K)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   December 9, 2011

SHENGTAI PHARMACEUTICAL, INC.

 (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-51312 (Commission File Number)	54-2155579 (IRS Employer Identification No.)

Changda Road East Development District, Changle County Shandong, PRC  (Address of principal executive offices)	262400 (Zip Code)

Registrant’s telephone number, including area code: 011-86-536-6295802

Copies to:

Benjamin Tan, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32 Floor

New York, New York 10006

Phone: [phone]

Fax: [phone]

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

 

Item 8.01      Other Events.

On December 9, 2011, Shengtai Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced that its annual meeting will be held Monday, February 13, 2012 at 9:00 a.m., local time, at the Company’s headquarters at Changda Road East, Development District, Changle County, Shandong, The People’s Republic of China.  A copy of the related press release is attached hereto as Exhibit 99.1.

Item 9.01      Financial Statements and Exhibits.

 

(d)    Exhibits.

 

99.1

Press release dated December 9, 2011, issued by Shengtai Pharmaceuticals, Inc.

 

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	SHENGTAI PHARMACEUTICAL, INC.
Dated: December 9, 2011	By:	/s/ Qingtai Liu
	Name:	Qingtai Liu
	Title	Chief Executive Officer

 

 

 

---